In vitro susceptibility of Salmonella to various antimicrobial agents, including a new cephalosporin, Ro 13-9904

Chau, Pui Hing; Ng, W. S.; Ling, J. M.; Arnold, Keith

doi:10.1128/aac.19.1.8

Cited by 22 publications

(15 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ceftriaxone was more active than ampicillin, cefotaxime, piperacillin, cefamandole, or carbenicillin in a pneumococcal pneumonia model in mice. These studies indicate that ceftriaxone is a potent, broadspectrum cephalosporin with unusual pharmacokinetic properties.Ceftriaxone (Ro 13-9904), a 2-aminothiazolyl methoxyimino cephalosporin derivative, has exhibited high orders of activity, both in vitro (1,2,5,7,11,13,14,17, 18) …”

mentioning

confidence: 99%

See 1 more Smart Citation

In vivo activity of ceftriaxone (Ro 13-9904), a new broad-spectrum semisynthetic cephalosporin

Beskid¹,

Christenson²,

Cleeland³

et al. 1981

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Ceftriaxone (Ro 13-9904) was compared with other newer f3-lactam antibiotics for activity in experimental infections of mice with Enterobacteriaceae, Haemophilu influenzae, Pseudomonas aeruginosa, and gram-positive bacteria. Overall, ceftriaxone was equal or superior to cefotaxime and cefoperazone against systemic infections. All three drugs were highly potent against most organisms but were considerably less active against P. aeruginosa. However, ceftriaxone tended to be more active ihan the other two agents against 8 of the 10 P. aeruginosa strains tested. Ceftriaxone, cefmenoxime (SCE 1365), and moxalactam were all highly active against systemic infections with 16 strains of Enterobacteriaceae, whereas ceftriaxone was more active against infections with two strains of streptococci. When the drugs were administered at various time intervals before infection, ceftriaxone was superior to cefotaxime, cefmenoxime, and moxalactam. This suggested that ceftriaxone might be eliminated from mice more slowly than the other drugs. In the case of cefotaxime, this was directly confirmed by microbiological assays of plasma samples. In a murine meningitis model induced by Klebsiella penumoniae or Streptococcus pneumoniae, ceftriaxone was more active than ampicillin or cefotaxime. Ceftriaxone was more active than ampicillin, cefotaxime, piperacillin, cefamandole, or carbenicillin in a pneumococcal pneumonia model in mice. These studies indicate that ceftriaxone is a potent, broadspectrum cephalosporin with unusual pharmacokinetic properties.Ceftriaxone (Ro 13-9904), a 2-aminothiazolyl methoxyimino cephalosporin derivative, has exhibited high orders of activity, both in vitro (1,2,5,7,11,13,14,17, 18)

show abstract

mentioning

confidence: 99%

“…Ceftriaxone (Ro 13-9904), a 2-aminothiazolyl methoxyimino cephalosporin derivative, has exhibited high orders of activity, both in vitro (1,2,5,7,11,13,14,17, 18) …”

mentioning

confidence: 99%

In vivo activity of ceftriaxone (Ro 13-9904), a new broad-spectrum semisynthetic cephalosporin

Beskid¹,

Christenson²,

Cleeland³

et al. 1981

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…The MIC90 of ceftriaxone and cefotaxime for S. aureus (penicillin G susceptible or resistant) are in the range of 3.1 to 6.3 ,ug/ml, whereas moxalactam is slightly less active (1,8,11,18,23). All three of the drugs have been clinically effective in treating S. aureus infections, but none is as active against this bacterium as are 6 the penicillinase-resistant semisynthetic penicillins or the first-generation cephalosporins (8).…”

Section: Methodsmentioning

confidence: 99%

“…Cefoperazone (16), ceftazidime (20), and cefsulodin (25) may prove to be more effective antipseudomonal cephalosporins. Ceftriaxone, moxalactam, and cefotaxime have all proved to be extremely active against Salmonella species (6,8), Shigella species (1, 18), Neisseria meningititis (18), Neisseria gonorrheae (including penicillin-resistant strains) (24,32), and Haemophilus influenzae (including ampicillin-resistant strains) (19,24).…”

Section: Methodsmentioning

confidence: 99%

Ceftriaxone: in vitro studies and clinical evaluation

Gnann¹,

Goetter²,

Elliott³

et al. 1982

Antimicrob Agents Chemother

View full text Add to dashboard Cite

The in vitro activity of ceftriaxone against 437 clinical isolates of gram-negative bacilli was determined. Ceftriaxone was found to have high in vitro activity against Enterobacteriaceae, with the exception of Enterobacter cloacae. Ceftriaxone was only minimally active against Pseudomonas aeruginosa and Acinetobacter calcoaceticus. We evaluated the clinical efficacy and toxicity of ceftriaxone in 55 adult patients. Bacterial infection was confirmed by the isolation of etiological bacteria in 30 patients. Infectious disorders treated included 10 pneumonias, 13 urinary tract infections, and 7 soft tissue or bone infections. Pathogens identified were 25 isolates of gram-negative bacilli, 5 isolates of Staphylococcus aureus, 5 isolates of pneumococci, and 4 isolates of other streptococci. The overall efficacy of ceftriaxone was excellent. The clinical cure rate was 93%, and the bacteriological cure rate was 93%. A total of 30 adverse reactions were noted in 22 of 55 patients receiving ceftriaxone, but only one necessitated discontinuation of treatment. Adverse effects frequently noted were elevated hepatic enzymes (16%), thrombocytosis (16%), and eosinophilia (8%). Ceftriaxone is an effective and well-tolerated antimicrobial agent that appears promising for the treatment of serious gram-negative bacillary infections.

show abstract

“…[17][18][19][20] Ceftriaxone is safe and efficacious against most clinical isolates of Salmonella and is now the preferred drug for MDRTF infections. 21,22 Reports of resistance to cephalosporins have been appearing at an increasing rate since 2006. It is pertinent to monitor the resistance characteristics of multidrug-resistant Salmonella infections to enable empirical therapy and the treatment of complications.…”

mentioning

confidence: 99%